As this share has grown, however, Novo shareholders should be aware that GLP-1 agonists have become an increasingly large ...

When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...

Only 13 states currently offer Medicaid coverage for GLP-1 drugs, but the number of prescriptions and overall spending has ...

The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

There's buzz around certain type 2 diabetes drugs, which not only help regulate blood sugar but can also lead to significant ...

Welcome to the healthier, happier world of 2030. Heart attacks and strokes are down 20%. A drop in food consumption has left ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

Patients taking Ozempic and other trendy injectables are going under the ... At the heart of these medications are two key ...